Carregant...
ASCO 2018 NSCLC highlights—combination therapy is key
Non-small cell lung cancer (NSCLC) treatment was booming at this year’s ASCO 2018 meeting as several well-performed phase III trials with practice-changing potential were presented. Thereby immune checkpoint blockade (ICB) consolidated its major role in the treatment of NSCLC patients without geneti...
Guardat en:
| Publicat a: | Memo |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Vienna
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6280781/ https://ncbi.nlm.nih.gov/pubmed/30595752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-018-0444-7 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|